Showing 1381-1390 of 1621 results for "".
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d
- Orasis Secures $78 Million to Support Commercial Launch of Presbyopia Eye Drop Qlosihttps://modernod.com/news/orasis-secures-78-million-to-support-commercial-launch-of-presbyopia-eye-drops-qlosi/2482474/Orasis Pharmaceuticals announced the completion of a $78 million Series D financing round to support the commercial launch of its presbyopia eye drop, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%. The funding round includes a $68 million equity investment&nb
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/Aurion Biotech announced it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Aurion Biotech Announces First Canadian Subject Dosed in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-canadian-subject-dosed-in-phase-1-2-clinical-trial/2482189/Aurion Biotech announced that it has dosed the first Canadian subject in its phase 1/2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- Nordic Group Appoints Eric Donnenfeld, MD, as Medical Advisory Board Chairhttps://modernod.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/Amring Pharmaceuticals, a subsidiary of Nordic Group, announced that ophthalmologist Eric D. Donnenfeld, MD, will chair its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, O
- Opthea Completes Enrollment in First Pivotal Trial of Sozinibercept for Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-first-pivotal-trial-with-sozinibercept/2482114/Opthea announced it has completed enrollment of all patients in the COAST phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet age-rela
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n